NHS Specialised Services Commissioning

Specialised Services Commisioning / Cholangiocarcinoma From 1st April 2013, the NHS Commissioning Board will be responsible for the management of the NHS and will be in charge of specialised services commissioning within the new NHS architecture.  These specialised services, which include the treatment of many rare cancers, have been published in a consultation document on-line – where all materials ca...

Read More

Specialist Viewpoint No 5 – Pathology

Specialist Viewpoint – or cholangiocarcinoma as they see it … Article 5 – Pathology AMMF is running a series of articles from specialists giving their viewpoint on cholangiocarcinoma diagnosis, treatments and research.  The fifth article in this series, covering pathology, falls into the diagnosis category. We are delighted that Rob Goldin, Professor of Liver and GI Pathology, Imperial Colle...

Read More

Value Based Pricing – a Position Statement

Value Based Pricing (VBP) was proposed by Government in 2010 as a key way to deliver improved access to medicines. But detail is lacking, even though confidential Department of Health (DH) and The Association of the British Pharmaceutical Industry (ABPI) negotiations have recently commenced. This is a critically important moment with respect to research and drug development in the UK.  It is vital that ...

Read More

AMMF receives a legacy

For the first time, AMMF has been privileged to receive a legacy from a will. AMMF came into contact with Chris and Nicki Jackson in early July 2011 when Chris had just been diagnosed with cholangiocarcinoma – they became AMMF supporters and remained in close touch throughout all Chris's treatments.  Chris was a man with a love of life and for the people in his life and, with Nicki by his side, he...

Read More

Querying the CC diagnosis to treatment pathway

Helen Morement from AMMF attended Cancer52’s briefing at the House of Lords on 18 October, where Professor Sir Mike Richards, National Cancer Director at NCAT (1), stated that the diagnosis and treatment path for the rare cancers is now, “GP for referral – general/district hospital for diagnosis – specialists/specialist centre for treatment”. In AMMF’s experience this pathway is often not fol...

Read More

Viewpoint No 4 – Detecting Cholangiocarcinoma

Specialist Viewpoint – or cholangiocarcinoma as they see it … Article 4 – Detecting Cholangiocarcinoma AMMF is running a series of articles from specialists giving their viewpoint on cholangiocarcinoma diagnosis, treatments and research.  The fourth article in this series falls into the research category. Earlier this year we were delighted and encouraged to hear that John Chetwood, a fina...

Read More

Specialist Viewpoint No 3

Specialist Viewpoint - or cholangiocarcinoma as they see it … Article 3 - the Surgeon's Viewpoint AMMF is running a series of articles from specialists giving their viewpoint on cholangiocarcinoma diagnosis, treatments and research. The third article in this series, from surgeon Professor Brian Davidson has now arrived, and what he has to say is very much to the point. From commenting, "As surg...

Read More

Chris Allum’s Memorial Football Match

Chris Allum ran the London Marathon earlier this year for AMMF in memory of his father, Charlie Allum, who died from cholangiocarcinoma in June 2011.   If you have read our marathon report, you will see that Chris has written very movingly of his experience of taking on this event, how he had a photo of himself and his Dad printed on the back of his running vest, and how he kept his Dad close to him th...

Read More

Radiofrequency Ablation Development

"Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction" Surgeons and engineers at Imperial College London have devised a new device which can deliver radiofrequency ablation (RFA) to cancers within the bile ducts of patients with advanced pancreatic cancer and cholangiocarcinoma. This isn’t a cure, but does keep the bile ducts open longer...

Read More

Biomarker update from Imperial College

In 2011, AMMF made a grant to Imperial College London to fund the work of Research Fellow, Dr Abigail Zabron, for a year. Abigail has now sent us an update on her work into cholangiocarcinoma biomarkers and on what is happening in the laboratory, and we are delighted to report that we have agreed a further grant to Imperial College to secure her second research year. “Over the past few months we have...

Read More